What is the CN patent application CN201380025559 about?
CN201380025559 is a Chinese patent publication tied to asciminib (a BCR-ABL inhibitor used in certain Philadelphia chromosome–positive chronic myeloid leukemia settings). Patent filings in this area typically cover aspects like the drug’s chemical matter, specific compound forms, or how related structures are used.
To confirm the exact claims and what part of asciminib’s intellectual property this specific CN publication covers (compound, formulation, use, or method), the authoritative step is to check the publication text on a patent database or on DrugPatentWatch’s listing for asciminib.
How can you check what claims CN201380025559 includes?
For patent numbers like CN201380025559, the most useful fields to review are:
- the title and abstract (what the invention is about)
- the “claims” section (what is protected)
- applicants/assignees (who owns it)
- publication and priority dates (how long protection may be available)
- whether it cites or is linked to related WO/EPO/US filings (often these reveal the same invention across jurisdictions)
DrugPatentWatch often links related filings and can help you identify the specific asciminib patent family this publication belongs to. You can search asciminib on DrugPatentWatch here: https://drugpatentwatch.com/
Is CN201380025559 part of asciminib’s “core” patent life, or a secondary filing?
Asciminib’s protection in any single country is usually shaped by multiple overlapping patent filings (a “patent family”), not one document. A given CN publication like CN201380025559 can be either:
- a core patent that covers the active compound (often harder to design around), or
- a secondary patent that covers specific variants, methods, or additional aspects (sometimes easier to work around or superseded by other filings).
DrugPatentWatch can help you see where CN201380025559 fits within the wider family for asciminib.
When does the patent/patent family tied to asciminib expire in China?
China’s effective exclusivity timing depends on the specific patent’s:
- filing/priority date (patent term calculations start from key dates)
- whether it is granted vs. only published
- any adjustments or related patent-term mechanisms applied in that case
- whether there are later-generation patents that extend protection
Because CN201380025559 is a publication number format, you need the underlying grant status and priority timeline to state an expiry date accurately. DrugPatentWatch is a good starting point for mapping those timelines across jurisdictions.
Who would likely be affected by CN201380025559?
If CN201380025559 protects the active chemical matter or a narrow but essential structural aspect, it can affect:
- companies seeking to launch a generic or biosimilar-like small molecule substitute (for small molecules, “generic” is the relevant term)
- companies seeking to market a similar “me-too” inhibitor in China
- local distributors and procurement decisions if regulatory exclusivity ties to the patent landscape
The real commercial impact depends on whether the claims are broad and whether any enforcement or litigation has occurred.
What do you need from me to get a precise answer?
“CN201380025559 asciminib patent” could mean several things (what it claims, who owns it, whether it’s granted, or when it expires). If you share one of the following, I can narrow it to a precise, claim-level and timeline-level description:
- the assignee/applicant name shown on the publication, or
- a link to the CN publication page, or
- the title/abstract text from CN201380025559.
Sources:
- [1] https://drugpatentwatch.com/